Clinical Neuroscience: is a branch of neuroscience that focuses on the scientific study of fundamental mechanisms that underlie diseases and disorders of the brain and central nervous system. It seeks to develop new ways of diagnosing such disorders and ultimately of developing novel treatments.
The implications of NIH BRAIN research stretch beyond traditional medical and research contexts. This LabRoots session will present recent developments at the intersection of neuroscience and...
What motivates patients to participate in clinical trials? Discussions most often revolve around potential study participants’ perception of therapeutic benefit. Misconceptions about th...
Developing new diagnostic and therapeutic tools for brain disorders is an ethical imperative and conducting human research with neural devices is a key step towards achieving that goal. Condu...
The NIH BRAIN Initiative aims to develop new tools and neurotechnologies to transform our understanding of brain function in health and disease. That knowledge is critical to enable novel the...
Humans have a remarkable ability to flexibly interact with the environment. A compelling demonstration of this cognitive flexibility is our ability to perform complex, yet previously un-pract...
Humans interact with their environment in countless ways and can switch seamlessly between activities. Even for seemingly simple tasks, a variety of sensory inputs and contextual cues are int...
The rapid formation of new memories and the recall of old memories to inform decisions is essential for human cognition, but the underlying neural mechanisms remain poorly understood. We util...
The human brain has a remarkable ability to store and retrieve information. Detailed memories can be formed after as little as one exposure, and those memories can be retained for decades. Im...
NIH representatives from the BRAIN Initiative will be presenting an overview of the NIH BRAIN Initiative and describing funding opportunity announcements (FOAs) supporting impacts in human ne...
Joshua Gordon, M.D., Ph.D., Director of the National Institute of Mental Health, will provide an overview of challenges and opportunities in mental health research. Dr. Gordon will present em...
DATE: March 5, 2019TIME: 10:00am PSTSingle cell analysis, starting with the earliest low parameter fluorescent experiments, helped define the major cell subsets of human ce...
An aptamer (also known as a synthetic antibody) is a stable DNA, RNA, or peptide ligand that binds with high affinity and specificity to targets such as small molecules, peptides, proteins, b...
Pharmaceutical research and development efforts are often both inefficient and suffer from a high attrition rate of drug candidates within the clinical phase of development. Most drug t...
The lung is a highly complex organ, comprised of more than 40 cell types that are responsible for various important functions, the lung’s complexity contributes to the subsequent challe...
This presentation will discuss and review the promise and potential of 3D Microtissues, and the challenges of using these Microtissues as Hazard ID tools. Lastly, we will discuss the potentia...
The goal of transforming one’s pipeline to a steady source of usable data is within our reach. Data that could be used for clinical insights or earlier in the drug discovery process. &n...
Experimental models that promise to replace animal tests that are currently required for drugs and chemicals are rapidly proliferating. This includes a number of novel solutions offered by bi...
Comparative oncology is the study of naturally-occurring cancers in pet animals (mainly dogs) to broaden and deepen our collective understanding of cancers in both companion species and human...
Approximately 30% of drugs have failed in human clinical trials due to adverse reactions despite promising pre-clinical studies, and another 60% fail due to lack of efficacy. The NIH Tissue C...
As we look towards data to help generate insight and analytics across the entire drug discovery value chain, learn how interconnected data is from the various stages of preclinical, clinical,...
Preclinical drug discovery is at the edge of a major transformation that promises to improve translation to the clinic through enhanced acquisition and advanced analysis of data. While an imp...
Animal welfare is the most important issue in any in vivo laboratory. The ability to detect and intervene in cases where the conditions of animals may be deteriorating as well as the ability...
The implications of NIH BRAIN research stretch beyond traditional medical and research contexts. This LabRoots session will present recent developments at the intersection of neuroscience and...
What motivates patients to participate in clinical trials? Discussions most often revolve around potential study participants’ perception of therapeutic benefit. Misconceptions about th...
Developing new diagnostic and therapeutic tools for brain disorders is an ethical imperative and conducting human research with neural devices is a key step towards achieving that goal. Condu...
The NIH BRAIN Initiative aims to develop new tools and neurotechnologies to transform our understanding of brain function in health and disease. That knowledge is critical to enable novel the...
Humans have a remarkable ability to flexibly interact with the environment. A compelling demonstration of this cognitive flexibility is our ability to perform complex, yet previously un-pract...
Humans interact with their environment in countless ways and can switch seamlessly between activities. Even for seemingly simple tasks, a variety of sensory inputs and contextual cues are int...
The rapid formation of new memories and the recall of old memories to inform decisions is essential for human cognition, but the underlying neural mechanisms remain poorly understood. We util...
The human brain has a remarkable ability to store and retrieve information. Detailed memories can be formed after as little as one exposure, and those memories can be retained for decades. Im...
NIH representatives from the BRAIN Initiative will be presenting an overview of the NIH BRAIN Initiative and describing funding opportunity announcements (FOAs) supporting impacts in human ne...
Joshua Gordon, M.D., Ph.D., Director of the National Institute of Mental Health, will provide an overview of challenges and opportunities in mental health research. Dr. Gordon will present em...
DATE: March 5, 2019TIME: 10:00am PSTSingle cell analysis, starting with the earliest low parameter fluorescent experiments, helped define the major cell subsets of human ce...
An aptamer (also known as a synthetic antibody) is a stable DNA, RNA, or peptide ligand that binds with high affinity and specificity to targets such as small molecules, peptides, proteins, b...
Pharmaceutical research and development efforts are often both inefficient and suffer from a high attrition rate of drug candidates within the clinical phase of development. Most drug t...
The lung is a highly complex organ, comprised of more than 40 cell types that are responsible for various important functions, the lung’s complexity contributes to the subsequent challe...
This presentation will discuss and review the promise and potential of 3D Microtissues, and the challenges of using these Microtissues as Hazard ID tools. Lastly, we will discuss the potentia...
The goal of transforming one’s pipeline to a steady source of usable data is within our reach. Data that could be used for clinical insights or earlier in the drug discovery process. &n...
Experimental models that promise to replace animal tests that are currently required for drugs and chemicals are rapidly proliferating. This includes a number of novel solutions offered by bi...
Comparative oncology is the study of naturally-occurring cancers in pet animals (mainly dogs) to broaden and deepen our collective understanding of cancers in both companion species and human...
Approximately 30% of drugs have failed in human clinical trials due to adverse reactions despite promising pre-clinical studies, and another 60% fail due to lack of efficacy. The NIH Tissue C...
As we look towards data to help generate insight and analytics across the entire drug discovery value chain, learn how interconnected data is from the various stages of preclinical, clinical,...
Preclinical drug discovery is at the edge of a major transformation that promises to improve translation to the clinic through enhanced acquisition and advanced analysis of data. While an imp...
Animal welfare is the most important issue in any in vivo laboratory. The ability to detect and intervene in cases where the conditions of animals may be deteriorating as well as the ability...
Follow
